Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
24 févr. 2023 08h00 HE
|
Timber Pharmaceuticals
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber...
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook
14 déc. 2022 08h30 HE
|
Timber Pharmaceuticals
Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc....
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
09 déc. 2022 16h05 HE
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
14 nov. 2022 08h00 HE
|
Timber Pharmaceuticals
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more...
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split
08 nov. 2022 12h10 HE
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Announces Halt of Common Stock Trading
03 nov. 2022 08h22 HE
|
Timber Pharmaceuticals
Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split ...
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis
25 oct. 2022 08h00 HE
|
Timber Pharmaceuticals
- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the...
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering
03 oct. 2022 09h00 HE
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
14 sept. 2022 08h00 HE
|
Timber Pharmaceuticals
European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING RIDGE, NJ, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency
29 août 2022 16h05 HE
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...